Short answer
Verastem, Inc. (VSTM) filed an 8-K current report with the SEC on June 23, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Verastem disclosed preliminary TARGET-D 101 Phase 1/2 data for investigational VS-7375.
Verastem, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Verastem disclosed preliminary TARGET-D 101 Phase 1/2 data for investigational VS-7375
- VS-7375 targets KRAS G12D-mutated advanced solid tumors as an oral ON/OFF inhibitor
- Investor call and webcast scheduled June 23, 2026, at 4:30 p.m. Eastern Time
- Presentation furnished as Exhibit 99.1, providing the substantive clinical-data detail
Item 8.01 · Other Events
- VS-7375 showed preliminary activity across PDAC, CRC and NSCLC, supporting expansion into registration-directed Phase 2 studies
- In mPDAC, 93% of patients at 900 mg QD achieved over 50% CA19-9 reductions; all 14 patients remained on treatment
- Safety favorable at 600 mg QD (n=57) and 900 mg QD (n=25), with mostly low-grade gastrointestinal adverse events
- 900 mg QD plus cetuximab was DLT-cleared in mCRC, enabling additional enrollment in TARGET-D 203
- Key catalysts include Phase 2 starts in mid-2026, broader enrollment completion by year-end, and planned Phase 3 initiations in the first half of 2027
Item EX-99.1 · Exhibit EX-99.1
- VS-7375 clinical update supports potential best-in-class positioning in KRAS G12D cancers, but evidence remains preliminary and non-randomized
- 150+ patients enrolled across Phase 1/2 cohorts covering pancreatic, colorectal, and lung cancers
- 900 mg once daily showed 93% CA19-9 reductions above 50% among 13 of 14 metastatic pancreatic cancer patients
- Primarily low-grade gastrointestinal toxicity, with diarrhea in 52% and nausea in 24% at 900 mg
- Phase 2 enrollment targeted for completion by end-2026, with three Phase 3 trials planned to start by first-half 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Verastem, Inc. 8-K filings
Get the next VSTM 8-K as it lands
Follow VSTM for push alerts, or ask the research agent what this filing means.